Analyst Price Target is $37.00
▲ +76.02% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Sierra Oncology in the last 3 months. The average price target is $37.00, with a high forecast of $39.00 and a low forecast of $35.00. The average price target represents a 76.02% upside from the last price of $21.02.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Sierra Oncology. This Buy consensus rating has held steady for over two years.
Sierra Oncology, Inc. is a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focuses on advancing targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded on May 8, 2003 and is headquartered in Vancouver, Canada.